Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of LY3415244 in Participants With Advanced Solid Tumors
jRCT2080224186Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of LY3415244 in advanced nonhematological malignancy, sponsored by Eli Lilly and Company. Started Dec 2018; status: completed.
02
Drugs
LY3415244
03
Conditions
advanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2080224186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224186.